Features of cGVHD according to transplantation type
| . | PBSC (n = 48) . | BM (n = 53) . | P . |
|---|---|---|---|
| Patients evaluable for cGVHD (%) | 42 (87) | 44 (83) | NS |
| Patients developing cGVHD (%)* | 31 (74) | 19 (43) | .004 |
| Patients developing extensive cGVHD (%)* | 21 (50) | 9 (20) | .004 |
| Patients developing limited cGVHD (%)* | 10 (24) | 10 (23) | NS |
| Time to onset of cGVHD, mo | |||
| Median | 6.0 | 4.1 | NS |
| Range | 3.3-17.4 | 3.1-12.9 | |
| Mode of onset of cGVHD (%) | |||
| De novo | 9 (29) | 2 (10) | NS |
| Quiescent | 7 (23) | 10 (53) | |
| Progressive | 15 (48) | 7 (37) | |
| Duration of immunosuppressive therapy, mo | |||
| Median | 27.0 | 18.0 | .03 |
| Range | 6.0-50.9 | 5.3-53.1 |
| . | PBSC (n = 48) . | BM (n = 53) . | P . |
|---|---|---|---|
| Patients evaluable for cGVHD (%) | 42 (87) | 44 (83) | NS |
| Patients developing cGVHD (%)* | 31 (74) | 19 (43) | .004 |
| Patients developing extensive cGVHD (%)* | 21 (50) | 9 (20) | .004 |
| Patients developing limited cGVHD (%)* | 10 (24) | 10 (23) | NS |
| Time to onset of cGVHD, mo | |||
| Median | 6.0 | 4.1 | NS |
| Range | 3.3-17.4 | 3.1-12.9 | |
| Mode of onset of cGVHD (%) | |||
| De novo | 9 (29) | 2 (10) | NS |
| Quiescent | 7 (23) | 10 (53) | |
| Progressive | 15 (48) | 7 (37) | |
| Duration of immunosuppressive therapy, mo | |||
| Median | 27.0 | 18.0 | .03 |
| Range | 6.0-50.9 | 5.3-53.1 |
Percentage of assessable patients. NS indicates not significant.